nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—S-Adenosylmethionine—MAT1A—type 2 diabetes mellitus	0.00575	0.189	CrCbGaD
Regadenoson—Ribavirin—ENPP1—type 2 diabetes mellitus	0.0053	0.174	CrCbGaD
Regadenoson—S-Adenosylmethionine—CBS—type 2 diabetes mellitus	0.0037	0.122	CrCbGaD
Regadenoson—Azacitidine—DNMT1—type 2 diabetes mellitus	0.00277	0.0908	CrCbGaD
Regadenoson—Adenosine monophosphate—PRKAA1—type 2 diabetes mellitus	0.00235	0.0772	CrCbGaD
Regadenoson—Vidarabine—DPP4—type 2 diabetes mellitus	0.00234	0.0767	CrCbGaD
Regadenoson—Adenosine triphosphate—PRKAA1—type 2 diabetes mellitus	0.00204	0.0669	CrCbGaD
Regadenoson—Adenosine—DPP4—type 2 diabetes mellitus	0.00187	0.0613	CrCbGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PRKAA1—type 2 diabetes mellitus	0.00126	0.00781	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—MTNR1B—type 2 diabetes mellitus	0.00125	0.00774	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—GCG—type 2 diabetes mellitus	0.00124	0.0077	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—type 2 diabetes mellitus	0.00124	0.00769	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—MC4R—type 2 diabetes mellitus	0.00121	0.00751	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—ABCC8—type 2 diabetes mellitus	0.0012	0.0394	CrCbGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRB3—type 2 diabetes mellitus	0.00116	0.00718	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Other—CCR5—type 2 diabetes mellitus	0.00115	0.00713	CbGpPWpGaD
Regadenoson—ADORA2A—Monoamine Transport—TNF—type 2 diabetes mellitus	0.00111	0.00692	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—CPT1A—type 2 diabetes mellitus	0.00111	0.0069	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GCGR—type 2 diabetes mellitus	0.00109	0.0068	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NAMPT—type 2 diabetes mellitus	0.00109	0.00677	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—GNB3—type 2 diabetes mellitus	0.00107	0.00663	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—AVP—type 2 diabetes mellitus	0.00105	0.00654	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—F7—type 2 diabetes mellitus	0.00103	0.00641	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—MTNR1B—type 2 diabetes mellitus	0.00102	0.00634	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GIPR—type 2 diabetes mellitus	0.00101	0.00625	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRB3—type 2 diabetes mellitus	0.00099	0.00615	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CCKAR—type 2 diabetes mellitus	0.000978	0.00608	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—SREBF1—type 2 diabetes mellitus	0.000971	0.00603	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—AKT1—type 2 diabetes mellitus	0.000964	0.0317	CrCbGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—ADCY5—type 2 diabetes mellitus	0.000952	0.00591	CbGpPWpGaD
Regadenoson—Adenosine monophosphate—SRC—type 2 diabetes mellitus	0.000951	0.0312	CrCbGaD
Regadenoson—ADORA2A—GPCR ligand binding—MC4R—type 2 diabetes mellitus	0.000921	0.00572	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—GHRL—type 2 diabetes mellitus	0.00092	0.00572	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—ADIPOQ—type 2 diabetes mellitus	0.000891	0.00554	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GIP—type 2 diabetes mellitus	0.000886	0.00551	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—MTNR1B—type 2 diabetes mellitus	0.000874	0.00543	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—AGTR2—type 2 diabetes mellitus	0.000855	0.00531	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCKAR—type 2 diabetes mellitus	0.000838	0.00521	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—EDNRB—type 2 diabetes mellitus	0.000819	0.00509	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—HTR2C—type 2 diabetes mellitus	0.000795	0.00494	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—EDNRA—type 2 diabetes mellitus	0.000773	0.0048	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—ADRA2A—type 2 diabetes mellitus	0.000757	0.0047	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—ADRB3—type 2 diabetes mellitus	0.000754	0.00468	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGTR2—type 2 diabetes mellitus	0.000733	0.00455	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CRHR1—type 2 diabetes mellitus	0.000728	0.00452	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PPARGC1A—type 2 diabetes mellitus	0.000725	0.00451	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—MTNR1A—type 2 diabetes mellitus	0.000716	0.00445	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—AVP—type 2 diabetes mellitus	0.000716	0.00445	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—SIRT1—type 2 diabetes mellitus	0.000702	0.00436	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—EDNRB—type 2 diabetes mellitus	0.000702	0.00436	CbGpPWpGaD
Regadenoson—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000692	0.000856	CcSEcCtD
Regadenoson—Shock—Valsartan—type 2 diabetes mellitus	0.000692	0.000855	CcSEcCtD
Regadenoson—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000689	0.000853	CcSEcCtD
Regadenoson—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000689	0.000853	CcSEcCtD
Regadenoson—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000687	0.00085	CcSEcCtD
Regadenoson—Ill-defined disorder—Irbesartan—type 2 diabetes mellitus	0.000687	0.00085	CcSEcCtD
Regadenoson—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000683	0.000845	CcSEcCtD
Regadenoson—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000683	0.000845	CcSEcCtD
Regadenoson—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000682	0.000844	CcSEcCtD
Regadenoson—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000682	0.000844	CcSEcCtD
Regadenoson—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000681	0.000843	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HTR2C—type 2 diabetes mellitus	0.000681	0.00423	CbGpPWpGaD
Regadenoson—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000681	0.000842	CcSEcCtD
Regadenoson—Somnolence—Gliclazide—type 2 diabetes mellitus	0.00068	0.000841	CcSEcCtD
Regadenoson—Hypertension—Metformin—type 2 diabetes mellitus	0.000677	0.000838	CcSEcCtD
Regadenoson—Urticaria—Glyburide—type 2 diabetes mellitus	0.000677	0.000837	CcSEcCtD
Regadenoson—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000676	0.000837	CcSEcCtD
Regadenoson—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000675	0.000835	CcSEcCtD
Regadenoson—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000674	0.000834	CcSEcCtD
Regadenoson—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000674	0.000833	CcSEcCtD
Regadenoson—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.000672	0.000831	CcSEcCtD
Regadenoson—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000669	0.000827	CcSEcCtD
Regadenoson—Chest pain—Metformin—type 2 diabetes mellitus	0.000668	0.000826	CcSEcCtD
Regadenoson—Myalgia—Metformin—type 2 diabetes mellitus	0.000668	0.000826	CcSEcCtD
Regadenoson—Malaise—Irbesartan—type 2 diabetes mellitus	0.000668	0.000826	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—MTNR1B—type 2 diabetes mellitus	0.000666	0.00414	CbGpPWpGaD
Regadenoson—Headache—Pioglitazone—type 2 diabetes mellitus	0.000665	0.000822	CcSEcCtD
Regadenoson—Syncope—Irbesartan—type 2 diabetes mellitus	0.000664	0.000821	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000663	0.00082	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—EDNRA—type 2 diabetes mellitus	0.000663	0.00412	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000661	0.000817	CcSEcCtD
Regadenoson—Discomfort—Metformin—type 2 diabetes mellitus	0.00066	0.000816	CcSEcCtD
Regadenoson—Nausea—Glipizide—type 2 diabetes mellitus	0.000658	0.000813	CcSEcCtD
Regadenoson—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000657	0.000813	CcSEcCtD
Regadenoson—Hypotension—Valsartan—type 2 diabetes mellitus	0.000657	0.000812	CcSEcCtD
Regadenoson—Vision blurred—Losartan—type 2 diabetes mellitus	0.000657	0.000812	CcSEcCtD
Regadenoson—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000655	0.00081	CcSEcCtD
Regadenoson—Pain—Gliclazide—type 2 diabetes mellitus	0.000654	0.000809	CcSEcCtD
Regadenoson—Tremor—Losartan—type 2 diabetes mellitus	0.000653	0.000807	CcSEcCtD
Regadenoson—Rash—Glimepiride—type 2 diabetes mellitus	0.000652	0.000806	CcSEcCtD
Regadenoson—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000651	0.000805	CcSEcCtD
Regadenoson—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000651	0.000805	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—MTNR1A—type 2 diabetes mellitus	0.00065	0.00404	CbGpPWpGaD
Regadenoson—Rash—Sitagliptin—type 2 diabetes mellitus	0.000649	0.000803	CcSEcCtD
Regadenoson—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000649	0.000803	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—GLP1R—type 2 diabetes mellitus	0.000649	0.00403	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—type 2 diabetes mellitus	0.000648	0.00403	CbGpPWpGaD
Regadenoson—Headache—Glimepiride—type 2 diabetes mellitus	0.000647	0.000801	CcSEcCtD
Regadenoson—Ill-defined disorder—Losartan—type 2 diabetes mellitus	0.000646	0.000799	CcSEcCtD
Regadenoson—Cough—Irbesartan—type 2 diabetes mellitus	0.000646	0.000799	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—GHRL—type 2 diabetes mellitus	0.000646	0.00401	CbGpPWpGaD
Regadenoson—Headache—Sitagliptin—type 2 diabetes mellitus	0.000645	0.000798	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000641	0.000792	CcSEcCtD
Regadenoson—Tinnitus—Ramipril—type 2 diabetes mellitus	0.00064	0.000791	CcSEcCtD
Regadenoson—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000639	0.00079	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—CCKAR—type 2 diabetes mellitus	0.000638	0.00397	CbGpPWpGaD
Regadenoson—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000638	0.000789	CcSEcCtD
Regadenoson—Flushing—Ramipril—type 2 diabetes mellitus	0.000637	0.000788	CcSEcCtD
Regadenoson—Angioedema—Losartan—type 2 diabetes mellitus	0.000637	0.000787	CcSEcCtD
Regadenoson—Insomnia—Valsartan—type 2 diabetes mellitus	0.000636	0.000786	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ADCY5—type 2 diabetes mellitus	0.000634	0.00394	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000633	0.000783	CcSEcCtD
Regadenoson—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000631	0.000781	CcSEcCtD
Regadenoson—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000631	0.00078	CcSEcCtD
Regadenoson—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.00063	0.000779	CcSEcCtD
Regadenoson—Myalgia—Irbesartan—type 2 diabetes mellitus	0.00063	0.000779	CcSEcCtD
Regadenoson—Chest pain—Irbesartan—type 2 diabetes mellitus	0.00063	0.000779	CcSEcCtD
Regadenoson—Shock—Metformin—type 2 diabetes mellitus	0.00063	0.000779	CcSEcCtD
Regadenoson—Insomnia—Orlistat—type 2 diabetes mellitus	0.000628	0.000777	CcSEcCtD
Regadenoson—Malaise—Losartan—type 2 diabetes mellitus	0.000628	0.000777	CcSEcCtD
Regadenoson—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000628	0.000777	CcSEcCtD
Regadenoson—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000628	0.000777	CcSEcCtD
Regadenoson—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000628	0.000777	CcSEcCtD
Regadenoson—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000627	0.000775	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000626	0.000774	CcSEcCtD
Regadenoson—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000626	0.000774	CcSEcCtD
Regadenoson—Somnolence—Valsartan—type 2 diabetes mellitus	0.000625	0.000773	CcSEcCtD
Regadenoson—Syncope—Losartan—type 2 diabetes mellitus	0.000625	0.000773	CcSEcCtD
Regadenoson—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000624	0.000772	CcSEcCtD
Regadenoson—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000623	0.00077	CcSEcCtD
Regadenoson—Skin disorder—Metformin—type 2 diabetes mellitus	0.000622	0.000769	CcSEcCtD
Regadenoson—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.00062	0.000767	CcSEcCtD
Regadenoson—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000619	0.000765	CcSEcCtD
Regadenoson—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000618	0.000765	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—GCGR—type 2 diabetes mellitus	0.000618	0.00384	CbGpPWpGaD
Regadenoson—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000616	0.000762	CcSEcCtD
Regadenoson—Palpitations—Losartan—type 2 diabetes mellitus	0.000616	0.000761	CcSEcCtD
Regadenoson—Nausea—Glimepiride—type 2 diabetes mellitus	0.000614	0.000759	CcSEcCtD
Regadenoson—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000612	0.000757	CcSEcCtD
Regadenoson—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000612	0.000757	CcSEcCtD
Regadenoson—Asthenia—Glyburide—type 2 diabetes mellitus	0.000611	0.000756	CcSEcCtD
Regadenoson—Cough—Losartan—type 2 diabetes mellitus	0.000608	0.000752	CcSEcCtD
Regadenoson—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000608	0.000752	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PPP2CA—type 2 diabetes mellitus	0.000608	0.00377	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000607	0.000751	CcSEcCtD
Regadenoson—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000605	0.000748	CcSEcCtD
Regadenoson—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000604	0.000747	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—FAS—type 2 diabetes mellitus	0.000603	0.00375	CbGpPWpGaD
Regadenoson—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000601	0.000744	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.0006	0.000742	CcSEcCtD
Regadenoson—Hypotension—Metformin—type 2 diabetes mellitus	0.000598	0.00074	CcSEcCtD
Regadenoson—Erythema—Ramipril—type 2 diabetes mellitus	0.000597	0.000739	CcSEcCtD
Regadenoson—Shock—Irbesartan—type 2 diabetes mellitus	0.000594	0.000735	CcSEcCtD
Regadenoson—Pain—Orlistat—type 2 diabetes mellitus	0.000594	0.000735	CcSEcCtD
Regadenoson—Chest pain—Losartan—type 2 diabetes mellitus	0.000593	0.000734	CcSEcCtD
Regadenoson—Myalgia—Losartan—type 2 diabetes mellitus	0.000593	0.000734	CcSEcCtD
Regadenoson—Arthralgia—Losartan—type 2 diabetes mellitus	0.000593	0.000734	CcSEcCtD
Regadenoson—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000593	0.000733	CcSEcCtD
Regadenoson—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000593	0.000733	CcSEcCtD
Regadenoson—Anxiety—Losartan—type 2 diabetes mellitus	0.000591	0.000731	CcSEcCtD
Regadenoson—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.00059	0.000729	CcSEcCtD
Regadenoson—Rash—Bromocriptine—type 2 diabetes mellitus	0.000588	0.000727	CcSEcCtD
Regadenoson—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000587	0.000726	CcSEcCtD
Regadenoson—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000587	0.000726	CcSEcCtD
Regadenoson—Discomfort—Losartan—type 2 diabetes mellitus	0.000586	0.000725	CcSEcCtD
Regadenoson—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000585	0.000724	CcSEcCtD
Regadenoson—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000584	0.000722	CcSEcCtD
Regadenoson—Headache—Bromocriptine—type 2 diabetes mellitus	0.000584	0.000722	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—PPARA—type 2 diabetes mellitus	0.000583	0.00362	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000583	0.000721	CcSEcCtD
Regadenoson—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000583	0.000721	CcSEcCtD
Regadenoson—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000575	0.000711	CcSEcCtD
Regadenoson—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000575	0.000711	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—IAPP—type 2 diabetes mellitus	0.000575	0.00357	CbGpPWpGaD
Regadenoson—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000572	0.000708	CcSEcCtD
Regadenoson—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000571	0.000706	CcSEcCtD
Regadenoson—Somnolence—Metformin—type 2 diabetes mellitus	0.000569	0.000704	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—GIPR—type 2 diabetes mellitus	0.000569	0.00353	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GRK5—type 2 diabetes mellitus	0.000569	0.00353	CbGpPWpGaD
Regadenoson—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000569	0.000703	CcSEcCtD
Regadenoson—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000568	0.000703	CcSEcCtD
Regadenoson—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000565	0.000698	CcSEcCtD
Regadenoson—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000564	0.000697	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GCGR—type 2 diabetes mellitus	0.000561	0.00349	CbGpPWpGaD
Regadenoson—Tremor—Ramipril—type 2 diabetes mellitus	0.00056	0.000692	CcSEcCtD
Regadenoson—Shock—Losartan—type 2 diabetes mellitus	0.000559	0.000692	CcSEcCtD
Regadenoson—Urticaria—Valsartan—type 2 diabetes mellitus	0.000559	0.000691	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—AGTR2—type 2 diabetes mellitus	0.000558	0.00347	CbGpPWpGaD
Regadenoson—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000558	0.00069	CcSEcCtD
Regadenoson—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000556	0.000687	CcSEcCtD
Regadenoson—Tachycardia—Losartan—type 2 diabetes mellitus	0.000555	0.000686	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IRS2—type 2 diabetes mellitus	0.000555	0.00345	CbGpPWpGaD
Regadenoson—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000554	0.000686	CcSEcCtD
Regadenoson—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000554	0.000685	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—LEP—type 2 diabetes mellitus	0.000554	0.00344	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000553	0.000684	CcSEcCtD
Regadenoson—Urticaria—Orlistat—type 2 diabetes mellitus	0.000552	0.000683	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.00055	0.000681	CcSEcCtD
Regadenoson—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.00055	0.00068	CcSEcCtD
Regadenoson—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000549	0.000679	CcSEcCtD
Regadenoson—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000549	0.000679	CcSEcCtD
Regadenoson—Angioedema—Ramipril—type 2 diabetes mellitus	0.000546	0.000675	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CALM1—type 2 diabetes mellitus	0.000545	0.00338	CbGpPWpGaD
Regadenoson—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000543	0.000671	CcSEcCtD
Regadenoson—Vomiting—Glyburide—type 2 diabetes mellitus	0.000542	0.00067	CcSEcCtD
Regadenoson—Malaise—Ramipril—type 2 diabetes mellitus	0.000539	0.000666	CcSEcCtD
Regadenoson—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000539	0.000666	CcSEcCtD
Regadenoson—Rash—Glyburide—type 2 diabetes mellitus	0.000537	0.000665	CcSEcCtD
Regadenoson—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000537	0.000664	CcSEcCtD
Regadenoson—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000537	0.000664	CcSEcCtD
Regadenoson—Syncope—Ramipril—type 2 diabetes mellitus	0.000536	0.000663	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—EDNRB—type 2 diabetes mellitus	0.000534	0.00332	CbGpPWpGaD
Regadenoson—Headache—Glyburide—type 2 diabetes mellitus	0.000534	0.00066	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—ARAP1—type 2 diabetes mellitus	0.000531	0.0033	CbGpPWpGaD
Regadenoson—Hypotension—Losartan—type 2 diabetes mellitus	0.000531	0.000657	CcSEcCtD
Regadenoson—Palpitations—Ramipril—type 2 diabetes mellitus	0.000528	0.000653	CcSEcCtD
Regadenoson—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000528	0.000652	CcSEcCtD
Regadenoson—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000525	0.000649	CcSEcCtD
Regadenoson—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000524	0.000648	CcSEcCtD
Regadenoson—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000524	0.000647	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000522	0.000645	CcSEcCtD
Regadenoson—Cough—Ramipril—type 2 diabetes mellitus	0.000521	0.000645	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—MC4R—type 2 diabetes mellitus	0.00052	0.00323	CbGpPWpGaD
Regadenoson—S-Adenosylmethionine—CYP2E1—type 2 diabetes mellitus	0.00052	0.0171	CrCbGaD
Regadenoson—ADORA2A—GPCR ligand binding—HTR2C—type 2 diabetes mellitus	0.000519	0.00322	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000518	0.000641	CcSEcCtD
Regadenoson—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000518	0.000641	CcSEcCtD
Regadenoson—Convulsion—Ramipril—type 2 diabetes mellitus	0.000518	0.00064	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GRK5—type 2 diabetes mellitus	0.000517	0.00321	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GIPR—type 2 diabetes mellitus	0.000517	0.00321	CbGpPWpGaD
Regadenoson—Pain—Irbesartan—type 2 diabetes mellitus	0.000517	0.000639	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—NOS2—type 2 diabetes mellitus	0.000516	0.0032	CbGpPWpGaD
Regadenoson—Insomnia—Losartan—type 2 diabetes mellitus	0.000514	0.000636	CcSEcCtD
Regadenoson—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000512	0.000633	CcSEcCtD
Regadenoson—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000511	0.000631	CcSEcCtD
Regadenoson—Urticaria—Metformin—type 2 diabetes mellitus	0.000509	0.000629	CcSEcCtD
Regadenoson—Chest pain—Ramipril—type 2 diabetes mellitus	0.000509	0.000629	CcSEcCtD
Regadenoson—Myalgia—Ramipril—type 2 diabetes mellitus	0.000509	0.000629	CcSEcCtD
Regadenoson—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000509	0.000629	CcSEcCtD
Regadenoson—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000507	0.000627	CcSEcCtD
Regadenoson—Anxiety—Ramipril—type 2 diabetes mellitus	0.000507	0.000627	CcSEcCtD
Regadenoson—Nausea—Glyburide—type 2 diabetes mellitus	0.000506	0.000626	CcSEcCtD
Regadenoson—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000506	0.000626	CcSEcCtD
Regadenoson—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000506	0.000626	CcSEcCtD
Regadenoson—Somnolence—Losartan—type 2 diabetes mellitus	0.000505	0.000625	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000505	0.000625	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—EDNRA—type 2 diabetes mellitus	0.000505	0.00313	CbGpPWpGaD
Regadenoson—Asthenia—Valsartan—type 2 diabetes mellitus	0.000504	0.000624	CcSEcCtD
Regadenoson—Discomfort—Ramipril—type 2 diabetes mellitus	0.000502	0.000621	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AVP—type 2 diabetes mellitus	0.000502	0.00312	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GIP—type 2 diabetes mellitus	0.000501	0.00311	CbGpPWpGaD
Regadenoson—Asthenia—Orlistat—type 2 diabetes mellitus	0.000498	0.000616	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR5—type 2 diabetes mellitus	0.000498	0.0031	CbGpPWpGaD
Regadenoson—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000498	0.000616	CcSEcCtD
Regadenoson—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000494	0.000611	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—ADRA2A—type 2 diabetes mellitus	0.000494	0.00307	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GHRL—type 2 diabetes mellitus	0.000492	0.00305	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ADCY5—type 2 diabetes mellitus	0.000488	0.00303	CbGpPWpGaD
Regadenoson—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000488	0.000603	CcSEcCtD
Regadenoson—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000487	0.000602	CcSEcCtD
Regadenoson—Pain—Losartan—type 2 diabetes mellitus	0.000486	0.000601	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—VPS26A—type 2 diabetes mellitus	0.000486	0.00302	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CALCA—type 2 diabetes mellitus	0.000486	0.00302	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IRS1—type 2 diabetes mellitus	0.000484	0.00301	CbGpPWpGaD
Regadenoson—Rash—Gliclazide—type 2 diabetes mellitus	0.000482	0.000597	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—PPARG—type 2 diabetes mellitus	0.000482	0.003	CbGpPWpGaD
Regadenoson—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000482	0.000596	CcSEcCtD
Regadenoson—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000481	0.000595	CcSEcCtD
Regadenoson—Urticaria—Irbesartan—type 2 diabetes mellitus	0.00048	0.000594	CcSEcCtD
Regadenoson—Shock—Ramipril—type 2 diabetes mellitus	0.00048	0.000593	CcSEcCtD
Regadenoson—Headache—Gliclazide—type 2 diabetes mellitus	0.000479	0.000593	CcSEcCtD
Regadenoson—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000478	0.000591	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—type 2 diabetes mellitus	0.000478	0.00297	CbGpPWpGaD
Regadenoson—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000478	0.000591	CcSEcCtD
Regadenoson—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000476	0.000588	CcSEcCtD
Regadenoson—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000475	0.000588	CcSEcCtD
Regadenoson—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000474	0.000586	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—MC4R—type 2 diabetes mellitus	0.000473	0.00294	CbGpPWpGaD
Regadenoson—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000471	0.000583	CcSEcCtD
Regadenoson—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000469	0.000579	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—PPP2CA—type 2 diabetes mellitus	0.000467	0.0029	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000465	0.000575	CcSEcCtD
Regadenoson—Dizziness—Valsartan—type 2 diabetes mellitus	0.000465	0.000575	CcSEcCtD
Regadenoson—Dizziness—Orlistat—type 2 diabetes mellitus	0.000459	0.000568	CcSEcCtD
Regadenoson—Asthenia—Metformin—type 2 diabetes mellitus	0.000459	0.000568	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABCC2—type 2 diabetes mellitus	0.000458	0.015	CrCbGaD
Regadenoson—Hypotension—Ramipril—type 2 diabetes mellitus	0.000456	0.000563	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GIP—type 2 diabetes mellitus	0.000455	0.00283	CbGpPWpGaD
Regadenoson—Nausea—Gliclazide—type 2 diabetes mellitus	0.000455	0.000562	CcSEcCtD
Regadenoson—Urticaria—Losartan—type 2 diabetes mellitus	0.000452	0.000559	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—GCG—type 2 diabetes mellitus	0.00045	0.00279	CbGpPWpGaD
Regadenoson—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000449	0.000556	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT2—type 2 diabetes mellitus	0.000448	0.00278	CbGpPWpGaD
Regadenoson—Vomiting—Valsartan—type 2 diabetes mellitus	0.000447	0.000553	CcSEcCtD
Regadenoson—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000445	0.000551	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000444	0.000549	CcSEcCtD
Regadenoson—Rash—Valsartan—type 2 diabetes mellitus	0.000443	0.000548	CcSEcCtD
Regadenoson—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000443	0.000548	CcSEcCtD
Regadenoson—Vomiting—Orlistat—type 2 diabetes mellitus	0.000442	0.000546	CcSEcCtD
Regadenoson—Insomnia—Ramipril—type 2 diabetes mellitus	0.000441	0.000545	CcSEcCtD
Regadenoson—Headache—Valsartan—type 2 diabetes mellitus	0.00044	0.000545	CcSEcCtD
Regadenoson—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000438	0.000542	CcSEcCtD
Regadenoson—Rash—Orlistat—type 2 diabetes mellitus	0.000438	0.000542	CcSEcCtD
Regadenoson—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000438	0.000541	CcSEcCtD
Regadenoson—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000438	0.000541	CcSEcCtD
Regadenoson—Headache—Orlistat—type 2 diabetes mellitus	0.000435	0.000538	CcSEcCtD
Regadenoson—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000435	0.000538	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—SERPINE1—type 2 diabetes mellitus	0.000434	0.0027	CbGpPWpGaD
Regadenoson—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000433	0.000536	CcSEcCtD
Regadenoson—Somnolence—Ramipril—type 2 diabetes mellitus	0.000433	0.000536	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—type 2 diabetes mellitus	0.000427	0.00265	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IRS2—type 2 diabetes mellitus	0.000427	0.00265	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRB3—type 2 diabetes mellitus	0.000426	0.00265	CbGpPWpGaD
Regadenoson—Dizziness—Metformin—type 2 diabetes mellitus	0.000423	0.000524	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000421	0.000521	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—CALM1—type 2 diabetes mellitus	0.000419	0.0026	CbGpPWpGaD
Regadenoson—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000419	0.000518	CcSEcCtD
Regadenoson—Nausea—Valsartan—type 2 diabetes mellitus	0.000418	0.000516	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—C3—type 2 diabetes mellitus	0.000417	0.00259	CbGpPWpGaD
Regadenoson—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000413	0.000511	CcSEcCtD
Regadenoson—Nausea—Orlistat—type 2 diabetes mellitus	0.000413	0.00051	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CRHR1—type 2 diabetes mellitus	0.000411	0.00256	CbGpPWpGaD
Regadenoson—Asthenia—Losartan—type 2 diabetes mellitus	0.000408	0.000505	CcSEcCtD
Regadenoson—Vomiting—Metformin—type 2 diabetes mellitus	0.000407	0.000503	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3R1—type 2 diabetes mellitus	0.000407	0.00253	CbGpPWpGaD
Regadenoson—Rash—Metformin—type 2 diabetes mellitus	0.000404	0.000499	CcSEcCtD
Regadenoson—Dermatitis—Metformin—type 2 diabetes mellitus	0.000403	0.000499	CcSEcCtD
Regadenoson—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000402	0.000497	CcSEcCtD
Regadenoson—Headache—Metformin—type 2 diabetes mellitus	0.000401	0.000496	CcSEcCtD
Regadenoson—Dizziness—Irbesartan—type 2 diabetes mellitus	0.0004	0.000494	CcSEcCtD
Regadenoson—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000399	0.000493	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGT—type 2 diabetes mellitus	0.000396	0.00246	CbGpPWpGaD
Regadenoson—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000389	0.000481	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—GNB3—type 2 diabetes mellitus	0.000388	0.00241	CbGpPWpGaD
Regadenoson—Urticaria—Ramipril—type 2 diabetes mellitus	0.000387	0.000479	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—ADRB3—type 2 diabetes mellitus	0.000387	0.0024	CbGpPWpGaD
Regadenoson—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000385	0.000477	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—MTNR1A—type 2 diabetes mellitus	0.000384	0.00239	CbGpPWpGaD
Regadenoson—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000384	0.000475	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—AVP—type 2 diabetes mellitus	0.000382	0.00238	CbGpPWpGaD
Regadenoson—Rash—Irbesartan—type 2 diabetes mellitus	0.000381	0.000471	CcSEcCtD
Regadenoson—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000381	0.000471	CcSEcCtD
Regadenoson—Nausea—Metformin—type 2 diabetes mellitus	0.00038	0.00047	CcSEcCtD
Regadenoson—Headache—Irbesartan—type 2 diabetes mellitus	0.000378	0.000468	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—MTNR1B—type 2 diabetes mellitus	0.000376	0.00234	CbGpPWpGaD
Regadenoson—Dizziness—Losartan—type 2 diabetes mellitus	0.000376	0.000465	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CRHR1—type 2 diabetes mellitus	0.000374	0.00232	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IRS1—type 2 diabetes mellitus	0.000372	0.00231	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GLP1R—type 2 diabetes mellitus	0.000367	0.00228	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—EDN1—type 2 diabetes mellitus	0.000364	0.00226	CbGpPWpGaD
Regadenoson—Vomiting—Losartan—type 2 diabetes mellitus	0.000362	0.000447	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CCKAR—type 2 diabetes mellitus	0.000361	0.00224	CbGpPWpGaD
Regadenoson—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000359	0.000444	CcSEcCtD
Regadenoson—Nausea—Irbesartan—type 2 diabetes mellitus	0.000359	0.000444	CcSEcCtD
Regadenoson—Rash—Losartan—type 2 diabetes mellitus	0.000359	0.000443	CcSEcCtD
Regadenoson—Dermatitis—Losartan—type 2 diabetes mellitus	0.000358	0.000443	CcSEcCtD
Regadenoson—Headache—Losartan—type 2 diabetes mellitus	0.000356	0.000441	CcSEcCtD
Regadenoson—Asthenia—Ramipril—type 2 diabetes mellitus	0.00035	0.000433	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—AKT2—type 2 diabetes mellitus	0.000345	0.00214	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MTNR1B—type 2 diabetes mellitus	0.000342	0.00212	CbGpPWpGaD
Regadenoson—Nausea—Losartan—type 2 diabetes mellitus	0.000338	0.000418	CcSEcCtD
Regadenoson—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000334	0.000413	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GLP1R—type 2 diabetes mellitus	0.000333	0.00207	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GCGR—type 2 diabetes mellitus	0.000332	0.00206	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCKAR—type 2 diabetes mellitus	0.000328	0.00203	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—type 2 diabetes mellitus	0.000327	0.00203	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCR5—type 2 diabetes mellitus	0.000325	0.00202	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—IAPP—type 2 diabetes mellitus	0.000325	0.00202	CbGpPWpGaD
Regadenoson—Dizziness—Ramipril—type 2 diabetes mellitus	0.000322	0.000399	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—C3—type 2 diabetes mellitus	0.000318	0.00197	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—TRPC6—type 2 diabetes mellitus	0.000317	0.00197	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	0.000315	0.00196	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3R1—type 2 diabetes mellitus	0.000313	0.00194	CbGpPWpGaD
Regadenoson—Vomiting—Ramipril—type 2 diabetes mellitus	0.00031	0.000383	CcSEcCtD
Regadenoson—Rash—Ramipril—type 2 diabetes mellitus	0.000307	0.00038	CcSEcCtD
Regadenoson—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000307	0.00038	CcSEcCtD
Regadenoson—Headache—Ramipril—type 2 diabetes mellitus	0.000305	0.000378	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GIPR—type 2 diabetes mellitus	0.000305	0.0019	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRK5—type 2 diabetes mellitus	0.000305	0.0019	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	0.000302	0.00188	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—AGT—type 2 diabetes mellitus	0.000302	0.00188	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—type 2 diabetes mellitus	0.000301	0.00187	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IAPP—type 2 diabetes mellitus	0.000295	0.00183	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—RELA—type 2 diabetes mellitus	0.000294	0.00183	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	0.000293	0.00182	CbGpPWpGaD
Regadenoson—Nausea—Ramipril—type 2 diabetes mellitus	0.00029	0.000358	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	0.000288	0.00179	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	0.000286	0.00178	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	0.000285	0.00177	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MC4R—type 2 diabetes mellitus	0.000279	0.00173	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	0.000279	0.00173	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	0.000278	0.00173	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	0.000274	0.00171	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	0.000274	0.0017	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GIP—type 2 diabetes mellitus	0.000269	0.00167	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	0.000266	0.00165	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CASP3—type 2 diabetes mellitus	0.000266	0.00165	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—type 2 diabetes mellitus	0.000264	0.00164	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	0.000259	0.00161	CbGpPWpGaD
Regadenoson—Cytarabine—CYP3A4—type 2 diabetes mellitus	0.000259	0.00849	CrCbGaD
Regadenoson—ADORA2A—Signaling Pathways—LEPR—type 2 diabetes mellitus	0.000255	0.00159	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GCG—type 2 diabetes mellitus	0.000254	0.00158	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	0.000253	0.00157	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GHRL—type 2 diabetes mellitus	0.000252	0.00157	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	0.00025	0.00155	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CALCA—type 2 diabetes mellitus	0.000249	0.00155	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCL2—type 2 diabetes mellitus	0.000249	0.00154	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NFKB1—type 2 diabetes mellitus	0.000248	0.00154	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	0.000244	0.00152	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TLE4—type 2 diabetes mellitus	0.000237	0.00147	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—SRC—type 2 diabetes mellitus	0.000231	0.00144	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GCG—type 2 diabetes mellitus	0.000231	0.00143	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRB3—type 2 diabetes mellitus	0.000229	0.00142	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	0.000227	0.00141	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CRHR1—type 2 diabetes mellitus	0.000221	0.00137	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	0.000219	0.00136	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AVP—type 2 diabetes mellitus	0.000216	0.00134	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—IL6—type 2 diabetes mellitus	0.000207	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	0.000206	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	0.000204	0.00127	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGFR—type 2 diabetes mellitus	0.000203	0.00126	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—type 2 diabetes mellitus	0.000203	0.00126	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SPRY2—type 2 diabetes mellitus	0.000202	0.00125	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	0.000202	0.00125	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GNB3—type 2 diabetes mellitus	0.000199	0.00124	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RBP4—type 2 diabetes mellitus	0.000197	0.00122	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GLP1R—type 2 diabetes mellitus	0.000197	0.00122	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AVP—type 2 diabetes mellitus	0.000196	0.00122	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MMP3—type 2 diabetes mellitus	0.000196	0.00122	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	0.000195	0.00121	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCKAR—type 2 diabetes mellitus	0.000194	0.0012	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—type 2 diabetes mellitus	0.000187	0.00116	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EDN1—type 2 diabetes mellitus	0.000187	0.00116	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	0.000184	0.00114	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—C3—type 2 diabetes mellitus	0.00018	0.00112	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	0.000177	0.0011	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	0.000175	0.00109	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IAPP—type 2 diabetes mellitus	0.000174	0.00108	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—INSR—type 2 diabetes mellitus	0.000173	0.00108	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AGT—type 2 diabetes mellitus	0.000171	0.00106	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TRPC6—type 2 diabetes mellitus	0.00017	0.00106	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	0.00017	0.00106	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AGTR2—type 2 diabetes mellitus	0.000169	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCR5—type 2 diabetes mellitus	0.000167	0.00104	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—C3—type 2 diabetes mellitus	0.000163	0.00101	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EDNRB—type 2 diabetes mellitus	0.000162	0.00101	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	0.000158	0.000979	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HTR2C—type 2 diabetes mellitus	0.000157	0.000977	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PSMD6—type 2 diabetes mellitus	0.000157	0.000977	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6—type 2 diabetes mellitus	0.000156	0.000968	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AGT—type 2 diabetes mellitus	0.000155	0.000962	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	0.000153	0.00095	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	0.000152	0.000946	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CYBA—type 2 diabetes mellitus	0.000152	0.000946	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	0.00015	0.00093	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLAT—type 2 diabetes mellitus	0.000149	0.000926	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GHRL—type 2 diabetes mellitus	0.000149	0.000926	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CALCA—type 2 diabetes mellitus	0.000147	0.000915	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT1—type 2 diabetes mellitus	0.000144	0.000893	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	0.000143	0.000889	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	0.000139	0.000861	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	0.000138	0.000857	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	0.000136	0.000847	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GCG—type 2 diabetes mellitus	0.000136	0.000847	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	0.000134	0.000833	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	0.000134	0.000831	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	0.000128	0.000793	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	0.000125	0.000779	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	0.000125	0.000778	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	0.000119	0.000737	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	0.000118	0.00073	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	0.000116	0.00072	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	0.000116	0.00072	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	0.000115	0.000717	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	0.000115	0.000714	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	0.000114	0.000706	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	0.000112	0.000696	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	0.000112	0.000693	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	0.00011	0.000685	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	0.000107	0.000665	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	0.000105	0.000651	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	0.0001	0.000624	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	9.86e-05	0.000612	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—C3—type 2 diabetes mellitus	9.63e-05	0.000598	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	9.19e-05	0.000571	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.16e-05	0.000569	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	9.15e-05	0.000569	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	9e-05	0.000559	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	8.97e-05	0.000557	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	8.97e-05	0.000557	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.87e-05	0.000551	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.46e-05	0.000525	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	8e-05	0.000497	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—INS—type 2 diabetes mellitus	7.66e-05	0.000476	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.54e-05	0.000468	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.41e-05	0.00046	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.41e-05	0.00046	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.37e-05	0.000458	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.04e-05	0.000437	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.72e-05	0.000417	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.72e-05	0.000417	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	6.32e-05	0.000393	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.76e-05	0.000358	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.7e-05	0.000354	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.67e-05	0.000352	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.39e-05	0.000335	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.33e-05	0.000331	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.23e-05	0.000325	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	4.97e-05	0.000309	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.84e-05	0.000301	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.44e-05	0.000276	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.36e-05	0.000271	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	3.35e-05	0.000208	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.09e-05	0.000192	CbGpPWpGaD
